SwathiPadmanabhan

Associate

Atlanta + 1.404.581.8401

Connect:

Share

Swathi Padmanabhan's practice focuses on capital markets, corporate governance, and federal securities law. She has represented public and private companies and underwriters in a wide range of corporate transactions, including initial public offerings, activist defense and proxy contests, public and private debt offerings, restructurings, tender offers, and exchange offers. In addition, Swathi advises clients on corporate governance, shareholder activism, securities laws, stock exchange rules and regulations, and periodic reporting responsibilities.

Swathi also has significant M&A experience and has represented public and private companies and private equity firms in mergers, acquisitions, divestitures, spin-offs, and joint ventures. She has represented clients in a variety of industries, including health care, life sciences, financial institutions, military, real estate, telecommunications, and the public sector.

Swathi has researched and published several articles pertaining to corporate and technology law matters, including first authoring an article on the importance of strategic technology transfer partnerships with respect to the enabling HPV vaccine technologies in Nature Biotechnology, which at the time of publication officials at the World Health Organization recognized as one of the most rigorous technical analyses written on the subject to date. Swathi serves as a member of the Advisory Council of the Atlanta Symphony Orchestra.

Experience

  • Bally's acquires Bet.Works for $125 million and announces strategic partnership with Sinclair BroadcastJones Day advised Bally's Corporation in its $125 million acquisition of Bet.Works, a U.S. based sports betting platform provider to operators in New Jersey, Iowa, Indiana, and Colorado, and a long-term strategic partnership with Sinclair Broadcast Group, Inc., pursuant to which 21 FOX RSN brands will be rebranded using the Bally’s name and Bally’s will integrate content into the 190 television stations that Sinclair owns, operates, or provides services to across 88 markets and sports networks.
  • Omnicom completes $800 million Senior Notes offeringJones Day represented Omnicom Group Inc., a leading global marketing and corporate communications company, in connection with its registered public offering of $800 million of 2.600% Senior Notes due 2031.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Helios Technologies acquires Balboa Water Group for $218.5 millionJones Day advised Helios Technologies in the $218.5 million acquisition of BWG Holdings I Corp. (operating as Balboa Water Group) from investment funds affiliated with AEA Investors LP.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
    • View All

    Additional Publications

    Publications Prior to Jones Day

     

    March 2014
    Tips and Tactics for Transmitting PHI by Email, coauthor, AHLA Connections

    Fall 2012
    Hacking for Lulz: Employing Expert Hackers to Combat Cyber Terrorism, 15 Vand. J. Ent. & Tech. L. 191

    2010
    Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India, Nature Biotechnology, Vol. 28

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.